磁抽搐治疗抑郁症的确证性疗效与安全性试验(CREST-MST):磁抽搐治疗对比电休克治疗的随机非劣效性试验研究方案
该研究为国际两中心、双盲、随机、非劣效性临床试验,计划纳入260例难治性抑郁症患者,比较磁抽搐治疗(MST)与右侧单侧超短脉宽电休克治疗(RUL-UB-ECT)的疗效。主要联合终点为抑郁缓解且认知副作用更优,次要终点为自杀意念改善。受试者每周接受2-3次治疗,持续七周或最多21次。研究于2018年6月26日开始入组,预计2024年7月完成招募,投稿时已随机入组117例。
要点
- MST与RUL-UB-ECT在难治性抑郁症中比较抑郁缓解及认知副作用的联合主要终点。
- 计划样本260例,每周2-3次治疗,持续七周或最多21次。
- 研究采用意向性治疗设计,评估抑郁严重度、自杀意念、主观副作用及认知表现。
核心结论
- 若MST抗抑郁疗效与ECT相当且认知安全性更优,则可能快速进入临床实践。
- MST给药方式与ECT几乎相同,北美多数ECT机构可随时采用MST。
研究设计与样本
- 国际两中心、双盲、随机、非劣效性临床试验,计划纳入260例难治性抑郁症患者。
- 比较MST与右侧单侧超短脉宽电休克治疗(RUL-UB-ECT)。
- 入组标准为18岁以上、符合MINI诊断的非精神病性重性抑郁障碍的住院或门诊患者,且满足疾病严重度和全部入选标准。
- 受试者随机接受MST或RUL-UB-ECT,每周2-3次,持续七周或最多21次治疗。
- 采用意向性治疗设计,在治疗前、治疗中及治疗后评估抑郁严重度、自杀意念、主观副作用和认知表现。
主要发现
- 主要联合终点为抑郁缓解且认知副作用更优。
- 次要终点为自杀意念改善。
- 研究于2018年6月26日开始入组,预计2024年7月完成招募;投稿时已入组并随机117例参与者。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Electroconvulsive therapy (ECT) is well-established and effective for treatment-resistant depression (TRD), but in Canada and the USA, less than 1% of patients with TRD receive ECT mainly due to its cognitive adverse effects (i.e. amnesia). Thus, new treatment alternatives for TRD are urgently needed. One such treatment is magnetic seizure therapy (MST). ECT involves applying a train of high-frequency electrical stimuli to induce a seizure, whereas MST involves applying a train of high-frequency magnetic stimuli to induce a seizure. METHODS: In this manuscript, we introduce our international, two-site, double-blinded, randomized, non-inferiority clinical trial to develop MST as an effective and safe treatment for TRD. This trial will compare the efficacy of MST to right unilateral ultra-brief pulse width electroconvulsive therapy (RUL-UB-ECT) with a combined primary endpoint of remission of depression and superior cognitive adverse effects in 260 patients with TRD. Amelioration of suicidal ideation will be assessed as a secondary endpoint. Inpatients or outpatients, over 18 years of age with a MINI International Neuropsychiatric Interview (MINI) diagnosis of non-psychotic major depressive disorder (MDD) can be enrolled in the study provided that they meet illness severity and full eligibility criteria. Participants are randomized to receive MST or RUL-UB ECT, 2-3 days per week over seven weeks, or a maximum of 21 treatments. The study will involve before-, during-, and after-treatment assessments of depression severity, suicidal ideation, subjective side-effects, and cognitive performance consistent with an intent-to-treat study design approach. DISCUSSION: Positive results from this trial could have an immediate and tremendous impact for patients with TRD. If MST demonstrates comparable antidepressant treatment efficacy to ECT, but with greater cognitive safety, it could rapidly be adopted into clinical practice. Indeed, given that the administration of MST is nearly identical to ECT, the majority of ECT facilities in North America could readily adopt MST. Furthermore, the potential for cognitive safety could lead to improved treatment acceptability. Healthcare providers, patients and care partners, and policymakers would therefore demand this form of convulsive therapy. TRIAL STATUS: Enrollment for this study began on June 26, 2018, and is estimated to complete recruitment by July 2024. At the time of submission, we have enrolled and randomized 117 participants. TRIAL REGISTRATION: ClinicalTrials.gov NCT03191058 , Registered on June 19, 2017. Primary sponsor: Daniel Blumberger (DMB), Principal Investigator Daniel.Blumberger@camh.ca , 416-535-8501 x 33662 Contact for public queries: DMB, Daniel.Blumberger@camh.ca Contact for scientific queries: ZJD, Zdaskalakis@health.ucsd.edu.
引用
- Daskalakis ZJ, Tamminga C, Throop A, et al. Confirmatory Efficacy and Safety Trial of Magnetic Seizure Therapy for Depression (CREST-MST): study protocol for a randomized non-inferiority trial of magnetic seizure therapy versus electroconvulsive therapy. Trials. 2021. PMID: 34749782. doi:10.1186/s13063-021-05730-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。